These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 16960863)

  • 41. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
    McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R
    Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
    Farlow MR; Small GW; Quarg P; Krause A
    Dement Geriatr Cogn Disord; 2005; 20(2-3):192-7. PubMed ID: 16088144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
    Rovers JM; Dautzenberg PL; ter Bruggen JP
    Tijdschr Gerontol Geriatr; 2006 Jul; 37(3):117-20. PubMed ID: 16886519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
    Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
    Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
    Weintraub D; Somogyi M; Meng X
    Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
    Farlow MR; Lilly ML;
    BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
    Wesnes KA; McKeith I; Edgar C; Emre M; Lane R
    Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
    Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
    Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates.
    Ehrt U; Brønnick K; De Deyn PP; Emre M; Tekin S; Lane R; Aarsland D
    Int J Geriatr Psychiatry; 2007 Oct; 22(10):980-5. PubMed ID: 17393542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of responders to rivastigmine: a prospective cohort study.
    Lemstra AW; Kuiper RB; Schmand B; van Gool WA
    Dement Geriatr Cogn Disord; 2008; 25(1):60-6. PubMed ID: 18033962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations.
    Santangelo G; Trojano L; Vitale C; Ianniciello M; Amboni M; Grossi D; Barone P
    Mov Disord; 2007 Dec; 22(16):2418-25. PubMed ID: 17894370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.